As of today (2024-04-25), Medpace Holdings's share price is $397.56.
Medpace Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $14.87. Hence, Medpace Holdings's Price-to-Free-Cash-Flow Ratio for today is 26.74.
The historical rank and industry rank for Medpace Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:
MEDP'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.56 Med: 18.76 Max: 35.32
Current: 32.88
During the past 11 years, Medpace Holdings's highest Price-to-Free-Cash-Flow Ratio was 35.32. The lowest was 12.56. And the median was 18.76.
MEDP's Price-to-Free-Cash-Flow is ranked worse than 62.64% of 91
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.41
vs MEDP: 32.88
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Medpace Holdings was 26.00% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 27.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 26.50% per year.
During the past 11 years, Medpace Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 41.30% per year. The lowest was -4.10% per year. And the median was 27.40% per year.
Medpace Holdings Price-to-Free-Cash-Flow Historical Data
The historical data trend for Medpace Holdings's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medpace Holdings's Price-to-Free-Cash-Flow
For the Diagnostics & Research subindustry, Medpace Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Price-to-Free-Cash-Flow falls into.
Medpace Holdings's Share Price of today is $397.56.
Medpace Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Medpace Holdings Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Medpace Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace Holdings (Medpace Holdings) Business Description
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 